Table 2.
Animal model | Treatment | Results | Comments | |
Saber et al[25] | DEN-induced HCC in mice | I. Sorafenib | Both treatments improved liver histology; II. reduced α-feto-protein and VEGF level | Inhibition of proliferation by involvement of NFкB pathway and cyclin D1 |
vs | ||||
II. ACEIs or ARBs | ||||
Saber et al[26] | DEN-induced HCC in mice | 1 Sorafenib | ACE-Is and ARBs monotherapy or plus sorafenib improved liver histology with regression to grade 1, almost restoration of lobular architecture | No survival improvement |
2 ACE-I ± Sorafenib | No additional effect when combination therapy was used | |||
3 ARB ± Sorafenib | ||||
Nasr et al[27] | DEN-induced HCC in mice | Leflunomide Perindopril Curcumin | All drugs abrogated: hepatic microvessel density, elevated VEGF; only curcumin reduced HIF-1α. Nodules reduced or absent | Combination of these agents: further inhibited neovascularization |
Mansour et al[29] | DEN + carbon tetra-chloride in rats | ACE-I ARBs | Significant reduction of tumor markers and hepatic growth factors | Liver histology amelioration correlated with VEGF, CD31 and FGF |
Yanase et al[30] | DEN-treated rats | combined effect of ACE-I and 5-fluorouracil | Inhibition of HCC growth, neovascularization (VEGF and CD31+ vessels suppression), and marked increase of apoptosis | In vitro studies on EC tubular formation confirm the anti-angiogenetic effect |
Male BALB/c mice with injections of BNL-HCC cells. | ||||
Yoshiji et al[31] | DEN-treated mice | Vit. K and ACE-I used singularly or in combination | Inhibitory effects by each compound on hepato-carcinogenesis, more potent when used in combination | Increased apoptosis in the tumor, w/o any effect on tumor cell proliferation; CD31 mRNA suppression |
Male BALB/c mice with injections of BNL-HCC cells | ||||
Yoshiji et al[32] | DEN-treated rats and human HCC cell lines | Vit. K or ACE-I alone or in combination | Chemopreventive effect on pre-neoplastic foci formation by single compounds, more potent when combined. | Inhibition of endothelial cell proliferation and tubular formation; reduction of CD31 mRNA expression. |
Yoshiji et al[33] | DEN-treated rats | Interferon, ACE-I used singularly or in combination | IFN or PE, when used singularly, significantly attenuated, in combination nearly abolished HCC | CD31 and VEGF mRNA expression were reduced; apoptosis was also reduced; no change of cell proliferation |
Yoshiji et al[34] | DEN-treated rats | Perindopril (ACE-I) | Inhibition of neo-vascularization and VEGF expression | Suppression of VEGF-induced tubular formation; no effect on endothelial cell proliferation in vitro |
Endothelial cells in vitro |
ACE-Is: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II type 1 receptor blockers; Vit.: Vitamine; DEN: Diethylnitrosamine; HCC: Hepatocellular carcinoma; VEGF: Vascular endothelial growth factor; HIF: Hypoxia-inducible factor.